Purpose
BioVie is driven by a sense of urgency to investigate new approaches for people affected by neurological and neurodegenerative disorders and advanced liver disease.
The company’s work spans inflammation, insulin signaling, cellular energy, epigenetics and vascular physiology, with clinical evidence as the standard for progress.
Leadership and governance
Corporate information
BioVie Inc. is a publicly traded clinical-stage biotechnology company. Company disclosures, financial statements and risk factors are available through its investor-relations site and SEC filings.
Evidence and compliance note
Development-stage information can change. Investigational candidates are not approved, and safety and efficacy have not been established. Review source documents and current regulatory disclosures.